Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Escherichia coli O2 antigen is a specific O-polysaccharide component of the lipopolysaccharide (LPS) located on the outer membrane of certain pathogenic E. coli strains. It serves as a key surface-exposed structure that facilitates bacterial survival by providing resistance to the host's complement-mediated killing and preventing phagocytosis (PubMed: 30201686). The O2 serotype is one of the most prevalent antigens found in extra-intestinal pathogenic E. coli (ExPEC), which are major contributors to urinary tract infections, bacteremia, and neonatal meningitis (PubMed: 29158483). Due to its high immunogenicity and prevalence in clinical isolates, the O2 antigen is a primary target for glycoconjugate vaccines, such as ExPEC9V, and therapeutic monoclonal antibodies (PubMed: 32814658). These interventions aim to elicit or supply opsonophagocytic antibodies that enhance the clearance of the bacteria by the host's immune system.
Induction of serotype-specific opsonophagocytic antibodies that facilitate the clearance of bacteria by immune cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli O2 antigen (O2 antigen).